Join to View Full Profile
51 N 39th StBldgPhiladelphia, PA 19104
Dr. Soule is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Benjamin Soule is based in New Jersey, with specialty training in Allergy & Immunology and currently works in new drug development. He completed his medical education at St. George's University, followed by a residency in Internal Medicine at Rutgers Health, and fellowships at the National Cancer Institute and NIH Clinical Center. Currently, he is a Vice President, Head of Clinical Development at Sun Pharma . His career in business development and clinical roles spans positions at Novo Nordisk and Bristol-Myers Squibb. Dr. Soule's expertise includes rheumatology, clinical research, drug development, and immunodeficiencies. He has several published studies across various high-impact journals. He has also conducted clinical trials focusing on diseases such as Chronic Granulomatous Disease and Wiskott-Aldrich Syndrome. His recognitions include Philadelphia "Top Docs" and CMS Meaningful Use Certification.
Education & Training
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 2007 - 2010
National Cancer InstitutePost-Doctoral Fellowship, 2004 - 2007
Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 2001 - 2004
St. George's University School of MedicineClass of 2001
Certifications & Licensure
PA State Medical License 2010 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014
- Philadelphia "Top Docs" 2011-2012
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Interleukin-2 Treatment for Wiskott-Aldrich Syndrome Start of enrollment: 2008 Oct 01
- Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System Start of enrollment: 2010 Jan 05
- Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease Start of enrollment: 2010 May 18
Publications & Presentations
PubMed
- 9 citationsSustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis.Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Thomas W J Huizinga, Gustavo Citera
Rheumatology and Therapy. 2023-06-01 - 14 citationsStudy design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial.John B Buse, Helene Nordahl Christensen, Brian J Harty, Julie Mitchell, Benjamin P Soule
BMJ Open Diabetes Research & Care. 2023-05-01 - 22 citationsThe value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosisGrace Kim, Jonathan G. Goldin, Wendy Hayes, Andrea Oh, Benjamin Soule
Therapeutic Advances in Respiratory Disease. 2021-03-29
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
